ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
CT radiomics showed no improvement beyond volume dynamics for early lesion-level size response to immunotherapy in metastatic melanoma.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluated whether CT intensity and texture radiomics provide predictive value beyond simple volume dynamics for lesion-level response prediction in metastatic melanoma treated with immune checkpoint inhibitors.
methodsWe conducted a retrospective multicenter study including 158 patients (1,626 lesions) from an internal cohort (n = 129 patients with standardized protocols) and an external cohort (n = 29 patients with heterogeneous protocols). The primary endpoint was binary lesion-level size response (clinical benefit vs. progressive disease) at the second follow-up. We trained and compared Random Forest classifiers to predict this endpoint using clinical variables, volumetric features, radiomics, and combined predictors derived from baseline and first follow-up imaging. Models were trained on the internal cohort using patient-grouped cross-validation and applied unchanged to the external cohort. Paired differences in AUC were assessed against a ± 0.05 equivalence margin.
resultsBaseline-only prediction of first follow-up response was near chance for all models. For predicting response at second follow-up, the volumetric model achieved an internal AUC of 0.84 [95% CI 0.78-0.88] and the radiomics model 0.86 [0.81-0.90]. In the external cohort, with 12 progression events, the volumetric and radiomics models achieved AUCs of 0.68 [0.50-0.85] and 0.68 [0.51-0.88], with no significant difference between any models. Organ-specific analysis showed no significant improvement from adding radiomics for any lesion site. Across all 288 radiomic features, the median absolute correlation with lesion volume was 0.37. Sensitivity analyses contained small or borderline gains that did not replicate externally.
conclusionsVolumetric features capture the primary predictive information for early lesion-level response, and CT radiomics showed no conclusive improvement over volume dynamics. Confirmation in larger independent cohorts is required before radiomic signatures can be recommended for this task. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42823717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.